Medicine and Dentistry
Glucose Tolerance
100%
Sitagliptin
100%
Therapeutic Procedure
83%
Drug
33%
Fat
33%
Insulin
33%
Gastric Inhibitory Polypeptide
33%
Gluconeogenesis
33%
Pancreatic Islet
33%
Maturity Onset Diabetes of the Young
16%
Group Therapy
16%
Gene
16%
Insulin Sensitivity
16%
Hormone
16%
Glucose
16%
Glucagon Like Peptide 1
16%
Incretin
16%
Antidiabetic Agent
16%
Dipeptidyl Peptidase IV
16%
Carboxy Terminal Sequence
16%
Gastrointestinal Hormone
16%
Hexapeptide
16%
Dipeptidyl Peptidase-4 Inhibitor
16%
Combined Therapy
16%
Body Weight Change
16%
Keyphrases
Glucose Tolerance
100%
Sitagliptin
100%
Xenin-25
100%
Glucose-dependent Insulinotropic Polypeptide
25%
High-fat Diet Mice
25%
Dipeptidyl peptidase-4 (DPP-4)
25%
Combination Treatment
25%
Islet Architecture
25%
Pancreatic Islets
25%
Treatment Regimen
12%
Type 2 Diabetes Mellitus (T2DM)
12%
Metabolic
12%
Treatment Group
12%
Insulin
12%
Insulin Action
12%
Beneficial Effects
12%
Polypeptide 1
12%
Biological Properties
12%
Glucagon-like peptide-1 (GLP-1)
12%
Body Weight Changes
12%
Therapeutic Potential
12%
Therapeutic Target
12%
Incretin Effect
12%
Hexapeptide
12%
Gut Hormones
12%
Inhibitory Activity
12%
Metabolic Benefits
12%
Combination Therapy
12%
Inhibitor Drug
12%
Antidiabetic Efficacy
12%
Pharmacology, Toxicology and Pharmaceutical Science
Glucose
100%
Sitagliptin
100%
Insulin
50%
Drug
33%
Mouse
33%
Gastric Inhibitory Polypeptide
33%
Fat
33%
Antidiabetic Agent
16%
Hormone
16%
Glucagon-Like Peptide-1
16%
Non Insulin Dependent Diabetes Mellitus
16%
Incretin
16%
Dipeptidyl Peptidase IV Inhibitor
16%
Dipeptidyl Peptidase IV
16%
Gastrointestinal Hormone
16%
Hexapeptide
16%